Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-07-22
1996-11-19
Barts, Samuel
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3147
Patent
active
055763316
DESCRIPTION:
BRIEF SUMMARY
This application was filed under 35 U.S.C. 371 from the application PCT/JP93/01700 filed Nov. 19, 1993.
BACKGROUND OF THE INVENTION
The present invention relates to an agent for preventing and treating disturbances of intestinal mucous membrane. More particularly, the present invention relates to an agent for preventing and treating disturbances of intestinal mucous membrane, comprising, as the active ingredient, a carbostyril derivative represented by the following general formula (I): ##STR1## (wherein, R is a halogen-atom (a fluorine atom, a chlorine atom, a bromine atom or an iodine atom); the substituent on the carbostyril skeleton is at the 3- or 4-position of the carbostyril skeleton; and the bond between the 3- and 4-positions of the carbostyril skeleton is a single bond or a double bond) or a salt thereof, preferably 2-(4-chlorobenzoylamino)-3-(2-quinolon-4-yl)propionic acid or a salt thereof.
[Prior Art and Problems to Be Solved by the Invention]
The carbostyril derivatives represented by the above general formula (I) and the processes for production of said derivatives are described in Japanese Patent Publication No. 63-35623, etc. and the utility of said derivatives as an inhibitor for gastric ulcer is known. Further, the utility of the derivatives as a gastritis-treating agent is described in Japanese Patent Application Kokai (Laid-Open) No. 3-74329, and the processes for producing those compounds of said derivatives having an optical activity are described in Japanese Patent Application Kokai (Laid-Open) No. 3-145468.
Furthermore, inhibiting effect of compounds of the present invention on reactive oxygen metabolites is described in Japan. J. Pharmacol., Vol. 49, pp. 441-448 (1989), and the gastric mucous membrane protectability of the present invention compounds is described in Folia pharmacol. japon., Vol. 97, pp. 371-380 (1991).
Disturbances of intestinal mucous membrane include simple and primary ulcer of small intestine, nonspecific ulcer of colon, ulcerative colitis induced by nonspecific inflammations, Crohn's disease, etc., all of which appear owing to unknown causes. Disturbances of intestinal mucous membrane also appear owing to known causes such as infections, circular disturbances, collagen disease, radiations, medicines and the like. These disturbances of intestinal mucous membrane are generally hard to cure and, in some cases, surgical treatments are applied thereto. As the medicinal therapy for the disturbances, there are used adrenocortical steroids, Salazopyrin, immunosuppressive agents, etc. However, the steroidal drugs show side effects when administered in a large amount over a long period of time, and the immunosuppressive agents must be carefully used because of the very harmful side effects. Hence, it is desired to develop a medicine which is effective to the treatment of intractable disturbances of intestinal mucous membrane and which can be used safely over a long period of time.
Nonsteroidal anti-inflammatory drugs (hereinafter referred to as NSAID), which are widely used for various diseases attended by inflammations such as arthritis, chronic rheumatoid arthritis and the like, are known to give rise to disturbances of intestinal mucous membrane. The administration of these drugs must therefore be stopped in the middle in some cases. In patients of chronic rheumatoid arthritis, the treatment of rheumatism must be continued even when disturbances of intestinal mucous membrane have appeared, which requires the continued use of NSAID in such cases and poses a problem.
Under such a situation, various attempts were made to administer NSAID without incurring any disturbance of intestinal mucous membrane. For example, it was attempted to use a drug such as Sucralfate, Ranitidine (a histamine H.sub.2 blocker) or the like in combination with NSAID [e.g. Caldwell, J. R., et al., Am. J. Med., Vol. 83, pp. 74-82, 1987, and Ehsanullah, R. S. B. et al., Br. Med. J., Vol. 297, pp. 1017-1021, 1988]. However, no satisfactory result has been obtained yet.
SUMMARY OF THE INVENTION
REFERENCES:
patent: 4578381 (1986-03-01), Uchida et al.
"Sucralfate Treatment of Nonsteroidal Anti-Inflammatory Drug-Induced Gastrointestinal Symptoms and Mucosal Damage", Caldwell et al., The American Journal of Medicine, vol. 83 (suppl. 3B), pp. 74-82, Sep. 28, 1987.
"Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine", Ehsanullah et al., British Medical Journal, vol. 297, pp. 1017-1021, Oct. 22, 1988.
"Effect of OPC-12759, a Novel Antiulcer Agent, on Chronic and Acute Experimental Gastric Ulcer, and Gastric Secretion in Rats", Yamasaki et al., Japan J. Pharmacol., vol. 49, No. 4, pp. 441-448, 1989.
"Protective effect of rebamipide (OPC-12759) on the gastric mucosa in rats and humans", Kawano et al., Folia pharmacol. japon., vol. 97, No. 6, pp. 371-380, 1991.
"Effect of Rebamipide on Mucus Secretion by Endogenous Prostaglandin-independent Mechanism in Rat Gastric Mucosa", Ishihara et al., Arzneim.-Forsch./Drug Res., vol. 42, No. 12, pp. 1462-1466, 1992.
Akiyama Kazue
Osaka Toshihiro
Sakurai Kazushi
Yamasaki Katsuya
Barts Samuel
Otsuka Pharmaceutical Co. Ltd.
LandOfFree
Agent for preventing and treating disturbances of intestinal muc does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agent for preventing and treating disturbances of intestinal muc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for preventing and treating disturbances of intestinal muc will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-541286